Premium
Immunolabeling pattern of syndecan‐1 expression may distinguish pagetoid Bowen's disease, extramammary Paget's disease, and pagetoid malignant melanoma in situ
Author(s) -
BayerGarner Ilene B.,
Reed Jon A.
Publication year - 2004
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/j.0303-6987.2004.00164.x
Subject(s) - pagetoid , syndecan 1 , pathology , extramammary paget's disease , immunohistochemistry , medicine , cdx2 , epidermis (zoology) , melanoma , bowen's disease , biology , disease , cell , cancer research , anatomy , basal cell , genetics , biochemistry , gene expression , gene , homeobox
The differential diagnosis of pagetoid cells within the epidermis rests primarily between pagetoid Bowen's disease (PBD), extramammary Paget's disease (EPD), and pagetoid malignant melanoma (MIS) in situ . Although morphologic clues are often helpful in differentiating these lesions, the use of immunohistochemistry is often necessary to arrive at the correct diagnosis. Syndecan‐1 is a cell‐surface proteoglycan that mediates adhesion between cells and the extracellular matrix, and between cells themselves. Twenty‐two cases of PBD, four cases of intraepidermal EPD, and 13 cases of MIS were examined for syndecan‐1 immunoreactivity. Cell‐membrane syndecan‐1 immunoreactivity was evident in PBD, cytoplasmic syndecan‐1 immunoreactivity was evident in EPD, whereas immunoreactivity for syndecan‐1 was not present in MIS. The patterns of syndecan‐1 immunoreactivity in these lesions may be a useful adjunct in the differentiation of PBD, EPD, and MIS.